ST. JOSEPH, Mich., Jan. 6 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and high quality manually curated databases for systems biology and pathway analysis, today announced that Bayer Schering Pharma AG has renewed its MetaCore licenses for another three years. Bayer Schering Pharma has programs for cancer, cardiovascular diseases and gynecological therapies and GeneGo has good coverage of these diseases and others. GeneGo is also in the process of building disease specific platforms in cancer and the cardiovascular area that include blueprint pathway maps for the disease, processes and mechanisms as well as offering public domain experimental data and disease ontologies.
"Bayer Schering Pharma was one of our first customers and we appreciate their loyalty," said Julie Bryant, Vice President of Business Development at GeneGo. "MetaCore is widely used in Bayer in multiple departments including bioinformatics, oncology, cardiology and women's health for data mining and analysis of multiple omics experimental data such as gene expression and proteomics."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.1(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.1(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company's web site at http://www.genego.com.
|SOURCE GeneGo, Inc.|
Copyright©2009 PR Newswire.
All rights reserved